National Institute of Public Health, University of Southern Denmark, Studiestræde 6, 1455, Copenhagen, Denmark.
Institute of Applied Economics and Health Research, N, 2200, Copenhagen, Denmark.
BMC Cardiovasc Disord. 2020 Jul 13;20(1):336. doi: 10.1186/s12872-020-01616-9.
Patients with acute coronary syndrome (ACS) are at high risk of recurrent cardiovascular (CV) event. The European guidelines recommend low-density lipoprotein cholesterol (LDL-C) levels < 1.8 mmol/L and early initiation of intensive lipid-lowering therapy (LLT) to reduce CV risk. In order to reduce the risk of further cardiac events, the study aimed to evaluate LDL-C goal attainment and LLT intensity in an incident ACS population.
A cohort study of patients with residency at Funen in Denmark at a first-ever ACS event registered within the period 2010-2015. Information on LLT use and LDL-C levels was extracted from national population registers and a Laboratory database at Odense University Hospital. Treatments and lipid patterns were evaluated during index hospitalization, at 6-month and 12-month follow-up.
Among 3040 patients with an LDL-C measurement during index hospitalization, 40.7 and 39.0% attained the recommended LDL-C target value (< 1.8 mmol/L) within 6- and 12-month follow-up, respectively. During 6- and 12-month follow-up, a total of 89.2% (20.2%) and 88.4% (29.7%) used LLT (intensive LLT). Of the intensive LLT users, 43.4 and 47.7% reached the LDL-C target value at 6- and 12-month follow-up. The frequency of lipid monitoring was low: 69.5, 77.7 and 53.6% in patients with a first-ever ACS during index hospitalization, 6- and 12-month follow-up, respectively.
Using national health registers and laboratory data, a considerably gap was observed between treatment guidelines and clinical practice in the management of dyslipidemia leaving very high-risk patients without adequate lipid management strategy. Therefore, improved lipid management strategies aimed at reaching treatment targets are warranted.
急性冠状动脉综合征(ACS)患者存在心血管(CV)事件复发的高风险。欧洲指南建议将低密度脂蛋白胆固醇(LDL-C)水平降低至<1.8mmol/L,并尽早开始强化降脂治疗(LLT)以降低 CV 风险。为了降低进一步发生心脏事件的风险,本研究旨在评估首发 ACS 人群中的 LDL-C 目标达标情况和 LLT 强度。
这是一项在丹麦菲英岛的患者队列研究,研究对象为在 2010 年至 2015 年期间首次出现 ACS 的患者。LLT 使用情况和 LDL-C 水平信息从全国人口登记册和奥胡斯大学医院的实验室数据库中提取。在住院期间、6 个月和 12 个月随访时评估治疗和血脂模式。
在 3040 名接受 LDL-C 测量的患者中,分别有 40.7%和 39.0%在 6 个月和 12 个月随访时达到了推荐的 LDL-C 目标值(<1.8mmol/L)。在 6 个月和 12 个月随访时,分别有 89.2%(20.2%)和 88.4%(29.7%)的患者使用了 LLT(强化 LLT)。在强化 LLT 使用者中,分别有 43.4%和 47.7%在 6 个月和 12 个月随访时达到 LDL-C 目标值。血脂监测的频率较低:在住院期间、6 个月和 12 个月随访时,首次 ACS 患者的血脂监测率分别为 69.5%、77.7%和 53.6%。
使用国家健康登记册和实验室数据,在血脂管理方面,治疗指南与临床实践之间存在相当大的差距,使极高危患者无法采用适当的血脂管理策略。因此,需要制定改善的血脂管理策略,以达到治疗目标。